Search results
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 5 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate< ...
WTKR anchor Kurt Williams spreads cancer awareness as he begins radiation treatment himself
The Virginian-Pilot· 2 days agoIn December, Kurt Williams lay on a doctor’s table at Urology of Virginia, wearing only a black...
King Charles: What kind of cancer treatment is available to him - and what impact could it have
The Independent via Yahoo News· 2 days agoHow often a person has a cycle of treatment and the length will depend on the type of cancer, what...
Doctors Explain What Prostate Cancer Screenings Involve
Men's Health· 5 days agoIF YOU’VE NEVER had a prostate cancer screening, you may worry that it will be embarrassing and...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 3 days agoBiotech Stocks: A Groundbreaking Cancer Treatment Novartis won Food and Drug Administration approval...
Brachytherapy for Prostate Cancer Linked to Higher Risk of Second Pelvic Malignancy
MedPage Today· 5 days agoPelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared...
How long cancer treatment lasts as Charles issues health update
Daily Express· 2 days agoWhile details around his diagnosis and treatment have remained private, oncologist Doctor Silvia...
PSA Detectable After Radical Prostatectomy
Medscape· 5 days agoFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.
Canadian doctors are using 'outdated' guidelines to screen for cancer, experts warn
CBC via Yahoo News· 4 days agoCarolyn Holland can't help wondering how many years of her life she's lost because her breast cancer...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
WTVO - WQRF Rockford· 5 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (lutetium Lu 177 dotatate) for the treatment of pediatric patients 12 years and ...